Pulmonary vascular disease

Pulmonary vascular disease encompasses a group of disorders that disrupt normal blood flow in the lungs, ranging from pulmonary arterial hypertension to chronic thromboembolic disease. These conditions often present with nonspecific symptoms such as breathlessness, fatigue, and exercise intolerance, leading to delayed recognition. Advances in imaging techniques, including CT pulmonary angiography and echocardiography, combined with right heart catheterization, have greatly improved diagnostic accuracy. The therapeutic landscape for pulmonary vascular disease has expanded in recent years, with the development of targeted pharmacologic agents that address vasoconstriction, vascular remodeling, and thrombosis. Endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin analogs, and soluble guanylate cyclase stimulators form the backbone of therapy for pulmonary arterial hypertension, offering improvements in functional capacity and quality of life. Surgical and interventional procedures such as pulmonary endarterectomy and balloon pulmonary angioplasty provide curative options for certain subtypes, particularly thromboembolic disease. Ongoing research into genetic mutations, endothelial dysfunction, and signaling pathways continues to drive innovation in novel therapies, including biologics and regenerative medicine approaches. Effective management requires multidisciplinary expertise, often involving pulmonologists, cardiologists, and hematologists working collaboratively. The evolving field of pulmonary vascular disease highlights the value of precision diagnostics, targeted treatments, and long-term monitoring in reducing mortality and improving patient outcomes across diverse populations.